Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 6
---
 April 26, 2023.

Concurrently with the
reverse stock split, and in order to continue meeting The NASDAQ Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares
requirement pursuant to Rule 5550(a)(4), on March 27, 2023 we effected a ratio change in the number of Ordinary Shares represented by
the Depositary Shares from 25 Ordinary Shares per Depositary Share to five Ordinary Shares per Depositary Share.

On June 14, 2023, we
held our annual general meeting of shareholders, or June AGM, and our shareholders passed resolutions, among other procedural items,
to approve the allotment of, and disapplication of pre-emption rights in respect of, up to 7.0 billion Ordinary Shares, or Shareholder
Approval. On June 14, 2023, we also held a separate general meeting of shareholders, or June GM, and our shareholders passed resolutions
to (x)(i) re-designate our deferred shares into A deferred shares, or the Re-Designation, and (ii) subdivide our Ordinary Shares of £0.02
nominal value each into one ordinary share of £0.001 nominal value and 19 B deferred Shares of £0.001 nominal value each,
each the Subdivision, and (y) adopt new articles of association, or the Articles of Association, which made consequential amendments
to the existing Articles of Association of the Company to reflect the Re-Designation and the Subdivision, together with certain other
changes to reflect that the Ordinary Shares were no longer admitted to trading on AIM. As is standard for deferred shares, each B deferred
share has very limited rights and is effectively valueless. The B deferred shares have the rights and restrictions as set out in the
Articles of Association and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company
or to receive a dividend or other distribution.

On July 5, 2023, and in an
effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a
ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and
in an effort to bring our Depositary Share price into